Merck seeks to develop novel T-cell engager therapies with TriTAC platform: GlobalData
The deal includes the novel HPN-217 and HPN-328 compounds, which are currently undergoing Phase II clinical trials for various…
Recover your password.
A password will be e-mailed to you.